Skip to main content
logo
TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
2.870
-0.100 (-3.37%)
At close: Aug 21, 2026, 4:00 PM EDT
3.050
+0.180 (6.27%)
After-hours: Aug 21, 2026, 7:56 PM EDT

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
7.925.775.957.158.43.4
Research & Development
17.4413.429.7112.2610.232.75
Operating Expenses
25.3619.1915.6619.4218.636.15
Operating Income
-25.36-19.19-15.66-19.42-18.63-6.15
Interest Expense
-0.01-0.01-0.03-0.06-0.03-0.1
Interest & Investment Income
0.220.0800.010.020
Currency Exchange Gain (Loss)
-0.09-0.11-0.06---
Other Non Operating Income (Expenses)
0.6-8-1.010.921.08-0.59
EBT Excluding Unusual Items
-24.64-27.23-16.76-18.55-17.56-6.84
Merger & Restructuring Charges
-8.79-8.79----
Gain (Loss) on Sale of Assets
--0---0
Other Unusual Items
1.471.58----
Pretax Income
-42.38-34.44-16.75-18.55-17.56-6.84
Income Tax Expense
0.460.23----
Net Income
-42.83-34.66-16.75-18.55-17.56-6.84
Preferred Dividends & Other Adjustments
3.451.610.03---
Net Income to Common
-46.28-36.27-16.79-18.55-17.56-6.84
Net Income Growth
------
Shares Outstanding (Basic)
110---
Shares Outstanding (Diluted)
110---
Shares Change
246.69%5392.22%----
EPS (Basic)
-51.08-52.59-1336.64---
EPS (Diluted)
-51.08-52.59-1336.64---
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-22.61-19.52-13.36-18.11-15.86-5.52
Free Cash Flow Per Share
-24.95-28.31-1063.68---
EBITDA
-25.26-19.12-15.57-19.3-18.54-6.11
D&A For EBITDA
0.10.080.090.120.10.04
EBIT
-25.36-19.19-15.66-19.42-18.63-6.15
SEC Filings: 10-K · 10-Q